期刊
CURRENT TOPICS IN MEDICINAL CHEMISTRY
卷 19, 期 23, 页码 2081-2097出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1568026619666190905164144
关键词
KRAS; Cancer treatment; Mutant cancers; Oncogene; Therapeutic target; Viral oncogene
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. Scientists have not successfully developed drugs that target KRAS, although efforts have been made last three decades. In this review, we highlight the emerging experimental strategies of impairing KRAS membrane localization and the direct targeting of KRAS. We also conclude the combinatorial therapies and RNA interference technology for the treatment of KRAS mutant cancers. Moreover, the virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据